Eli Lilly – Page 6

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

11 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO

11 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, Eli, Eli Lilly, IPO, liver safety, Obesity, Phase 2 trial

BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO

Zepbound Outperforms Wegovy in Weight Loss Trial, Offering Superior Efficacy

11 months ago talkbio0Tagged Clinical Trials, Eli, Eli Lilly, Nordisk, Obesity, semaglutide, Wegovy, Zepbound

Zepbound, Wegovy, weight loss, tirzepatide, semaglutide, clinical trial, obesity medication, Eli Lilly, Novo Nordisk

Eli Lilly Invests $3 Billion in Wisconsin Manufacturing Expansion to Meet Growing Demand for Diabetes and Obesity Medicines

11 months ago talkbio0Tagged Diabetes, Eli, Eli Lilly, expansion, Investments, Manufacturing, Obesity, Surgical construction, Wisconsin

Eli Lilly, Wisconsin, manufacturing expansion, diabetes, obesity, pharmaceuticals, investment, job creation

Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study

11 months ago talkbio0Tagged Eli, Eli Lilly, Nordisk, Obesity, SURMOUNT-5, Wegovy, Weight Loss, Zepbound

Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5

Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models

12 months ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, healthcare litigation, HRSA, Johnson & Johnson, pharmaceutical pricing, rebate, Study models

340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation

Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events

12 months ago talkbio0Tagged Cardiovascular system, cholesterol, Eli, Eli Lilly, Lipoprotein(a ), Lp(a ), Muvalaplin, oral drug, Phase 2 Clinical Trials, Risk

Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction

Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth

12 months ago talkbio0Tagged competition, Drug Industry, Eli, Eli Lilly, financial results, issues, Market, Nordisk, Obesity, Pricing, Q3 2024, Weight loss therapies

Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues